Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Sanofi says European Commission approves Aubagio for children and adolescents » 09:50
06/18/21
06/18
09:50
06/18/21
09:50
SNY

Sanofi

$52.27 /

-0.95 (-1.79%)

The European Commission…

The European Commission has approved Aubagio for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis, or RRMS, Sanofi announced. "The approval confirms Aubagio as the first oral multiple sclerosis therapy for first-line treatment of children and adolescents with MS in the European Union," the company said.

ShowHide Related Items >><<
SNY Sanofi
$52.27 /

-0.95 (-1.79%)

SNY Sanofi
$52.27 /

-0.95 (-1.79%)

05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
SNY Sanofi
$52.27 /

-0.95 (-1.79%)

SNY Sanofi
$52.27 /

-0.95 (-1.79%)

SNY Sanofi
$52.27 /

-0.95 (-1.79%)

Thursday
Recommendations
SC rejection a potential read-through for Duke NC IRP process, says RBC Capital » 15:07
06/17/21
06/17
15:07
06/17/21
15:07
DUK

Duke Energy

$102.45 /

+0.63 (+0.62%)

Commenting on South…

Commenting on South Carolina Commission's decision to reject Duke Energy's IRPs and require several modifications, RBC Capital analyst Shelby Tucker says he believes the rejection could be seen as a read-through for the company's ongoing IRP process in North Carolina. Among the multitude of modifications, Duke must now prepare additional load forecast scenarios, reprice its natural gas forecasts, and utilize third-party solar PPAs as a resource, the analyst notes. While the impacts on the overall timeline remain unclear to Tucker, the analyst expects that the sheer volume of requests will require a meaningful update from Duke. Tucker has an Outperform rating and a price target of $109 on the shares.

ShowHide Related Items >><<
DUK Duke Energy
$102.45 /

+0.63 (+0.62%)

DUK Duke Energy
$102.45 /

+0.63 (+0.62%)

05/18/21 Morgan Stanley
Morgan Stanley sees 'low probability' Duke Energy and Elliott reach agreement
05/12/21 Mizuho
Duke Energy price target raised to $105 from $96 at Mizuho
04/14/21 Credit Suisse
Duke Energy price target raised to $104 from $96 at Credit Suisse
04/14/21 Wells Fargo
Duke Energy price target raised to $104 from $97 at Wells Fargo
DUK Duke Energy
$102.45 /

+0.63 (+0.62%)

DUK Duke Energy
$102.45 /

+0.63 (+0.62%)

DUK Duke Energy
$102.45 /

+0.63 (+0.62%)

Upgrade
TD upgrades Altice USA to Buy ahead of second half growth pickup » 11:30
06/17/21
06/17
11:30
06/17/21
11:30
ATUS

Altice USA

$33.73 /

-0.02 (-0.06%)

, CMCSA

Comcast

$57.34 /

+0.2 (+0.35%)

, CHTR

Charter

$694.01 /

+11.78 (+1.73%)

TD Securities analyst…

TD Securities analyst Vince Valentini earlier today upgraded Altice USA (ATUS) to Buy from Hold with a price target of $43, up from $40, after assuming primary coverage of the name. The second quarter has historically been a seasonally slow quarter for broadband, and the upcoming quarter will be no different, Valentini told investors in a research note. Altice management has been consistent in saying that the first half of the year will be a set-up for growth in the latter half in its core cable business, specifically the broadband business, adds the analyst. Given the underperformance of Altice USA relative to peers Comcast (CMCSA) and Charter (CHTR) year-to-date, Valentini upgraded the shares to Buy. He views the stock's "current discount as excessive."

ShowHide Related Items >><<
CMCSA Comcast
$57.34 /

+0.2 (+0.35%)

CHTR Charter
$694.01 /

+11.78 (+1.73%)

ATUS Altice USA
$33.73 /

-0.02 (-0.06%)

ATUS Altice USA
$33.73 /

-0.02 (-0.06%)

05/24/21 HSBC
Altice USA price target raised to $37 from $34 at HSBC
05/18/21
Fly Intel: Top five analyst downgrades
05/18/21 BofA
BofA downgrades 'show me story' Altice USA to Underperform
05/18/21 BofA
Altice USA downgraded to Underperform from Neutral at BofA
CMCSA Comcast
$57.34 /

+0.2 (+0.35%)

05/24/21 HSBC
Comcast price target raised to $64 from $56 at HSBC
05/18/21 Benchmark
Comcast selloff on Discovery-WarnerMedia news 'excessive,' says Benchmark
05/17/21 Citi
Discovery upgraded to Buy from Neutral at Citi
05/04/21 Deutsche Bank
Comcast price target raised to $65 from $60 at Deutsche Bank
CHTR Charter
$694.01 /

+11.78 (+1.73%)

06/02/21 Citi
Liberty Broadband price target raised to $198 from $193 at Citi
06/02/21 Citi
Charter price target raised to $724 from $708 at Citi
05/24/21 Benchmark
Benchmark does not 'attach any credence' to idea AT&T could buy Charter
05/24/21 HSBC
Charter price target raised to $700 from $650 at HSBC
CMCSA Comcast
$57.34 /

+0.2 (+0.35%)

CHTR Charter
$694.01 /

+11.78 (+1.73%)

ATUS Altice USA
$33.73 /

-0.02 (-0.06%)

  • 13
    Aug
  • 23
    Jun
CMCSA Comcast
$57.34 /

+0.2 (+0.35%)

CHTR Charter
$694.01 /

+11.78 (+1.73%)

CMCSA Comcast
$57.34 /

+0.2 (+0.35%)

CHTR Charter
$694.01 /

+11.78 (+1.73%)

ATUS Altice USA
$33.73 /

-0.02 (-0.06%)

CMCSA Comcast
$57.34 /

+0.2 (+0.35%)

On The Fly
Micron downgrade, AT&T upgrade among today's top calls on Wall Street » 10:01
06/17/21
06/17
10:01
06/17/21
10:01
MU

Micron

$80.55 /

+0.04 (+0.05%)

, T

AT&T

$29.02 /

-0.04 (-0.14%)

, VZ

Verizon

$56.66 /

+0.02 (+0.04%)

, DISCA

Discovery

$30.32 /

-0.13 (-0.43%)

, HNST

Honest Company

$16.31 /

-1.4 (-7.91%)

, NKE

Nike

$129.08 /

-1.27 (-0.97%)

, SWK

Stanley Black & Decker

$196.90 /

+0.14 (+0.07%)

Check out today's top…

ShowHide Related Items >><<
VZ Verizon
$56.66 /

+0.02 (+0.04%)

T AT&T
$29.02 /

-0.04 (-0.14%)

SWK Stanley Black & Decker
$196.90 /

+0.14 (+0.07%)

NKE Nike
$129.08 /

-1.27 (-0.97%)

MU Micron
$80.55 /

+0.04 (+0.05%)

DISCA Discovery
$30.32 /

-0.13 (-0.43%)

MU Micron
$80.55 /

+0.04 (+0.05%)

06/17/21
Fly Intel: Top five analyst downgrades
06/17/21 Lynx
Micron downgraded to Sell from Hold at Lynx
05/28/21 Citi
Lenovo, HP, Dell earnings good news for Intel and AMD, says Citi
05/26/21 Evercore ISI
Micron pullback an 'excellent' buying opportunity, says Evercore ISI
T AT&T
$29.02 /

-0.04 (-0.14%)

06/17/21
Fly Intel: Top five analyst upgrades
06/17/21 Scotiabank
AT&T upgraded to Sector Perform on reduced secular risk at Scotiabank
06/16/21 Scotiabank
AT&T upgraded to Sector Perform from Underperform at Scotiabank
06/16/21 Pivotal Research
Dish upgraded to Buy from Hold at Pivotal Research
VZ Verizon
$56.66 /

+0.02 (+0.04%)

05/24/21 HSBC
Verizon price target raised to $62 from $58 at HSBC
04/27/21
Fly Intel: Top five analyst downgrades
04/27/21 MoffettNathanson
Verizon downgraded to Neutral from Buy at MoffettNathanson
04/27/21 MoffettNathanson
Verizon downgraded to Neutral from Buy at MoffettNathanson
DISCA Discovery
$30.32 /

-0.13 (-0.43%)

05/24/21
Fly Intel: Top five analyst downgrades
05/24/21 Morgan Stanley
AT&T price target lowered to $32 from $34 at Morgan Stanley
05/24/21 MoffettNathanson
MoffettNathanson downgrades Discovery to Neutral after WarnerMedia deal news
05/24/21 MoffettNathanson
Discovery downgraded to Neutral from Buy at MoffettNathanson
HNST Honest Company
$16.31 /

-1.4 (-7.91%)

06/17/21 Loop Capital
Honest Company price target raised to $20 from $18 at Loop Capital
06/17/21 Jefferies
Honest success in skin and personal care encouraging, says Jefferies
06/17/21 JPMorgan
Honest Company should be bought on earnings selloff, says JPMorgan
NKE Nike
$129.08 /

-1.27 (-0.97%)

06/17/21 OTR Global
Nike downgraded to Mixed from Positive at OTR Global
06/16/21 Morgan Stanley
Nike price target raised to $185 from $172 at Morgan Stanley
06/14/21 UBS
Nike price target lowered to $170 from $175 at UBS
05/13/21
Fly Intel: Top five analyst initiations
SWK Stanley Black & Decker
$196.90 /

+0.14 (+0.07%)

06/17/21 Gabelli
Stanley Black & Decker upgraded to Buy from Hold at Gabelli
04/13/21 Deutsche Bank
Stanley Black & Decker price target raised to $221 from $215 at Deutsche Bank
04/07/21 JPMorgan
Stanley Black & Decker price target raised to $206 from $200 at JPMorgan
VZ Verizon
$56.66 /

+0.02 (+0.04%)

T AT&T
$29.02 /

-0.04 (-0.14%)

SWK Stanley Black & Decker
$196.90 /

+0.14 (+0.07%)

NKE Nike
$129.08 /

-1.27 (-0.97%)

MU Micron
$80.55 /

+0.04 (+0.05%)

HNST Honest Company
$16.31 /

-1.4 (-7.91%)

DISCA Discovery
$30.32 /

-0.13 (-0.43%)

  • 05
    May
  • 14
    Apr
VZ Verizon
$56.66 /

+0.02 (+0.04%)

T AT&T
$29.02 /

-0.04 (-0.14%)

SWK Stanley Black & Decker
$196.90 /

+0.14 (+0.07%)

NKE Nike
$129.08 /

-1.27 (-0.97%)

MU Micron
$80.55 /

+0.04 (+0.05%)

HNST Honest Company
$16.31 /

-1.4 (-7.91%)

DISCA Discovery
$30.32 /

-0.13 (-0.43%)

VZ Verizon
$56.66 /

+0.02 (+0.04%)

T AT&T
$29.02 /

-0.04 (-0.14%)

SWK Stanley Black & Decker
$196.90 /

+0.14 (+0.07%)

NKE Nike
$129.08 /

-1.27 (-0.97%)

MU Micron
$80.55 /

+0.04 (+0.05%)

HNST Honest Company
$16.31 /

-1.4 (-7.91%)

DISCA Discovery
$30.32 /

-0.13 (-0.43%)

VZ Verizon
$56.66 /

+0.02 (+0.04%)

T AT&T
$29.02 /

-0.04 (-0.14%)

NKE Nike
$129.08 /

-1.27 (-0.97%)

MU Micron
$80.55 /

+0.04 (+0.05%)

HNST Honest Company
$16.31 /

-1.4 (-7.91%)

DISCA Discovery
$30.32 /

-0.13 (-0.43%)

Upgrade
Fly Intel: Top five analyst upgrades » 09:55
06/17/21
06/17
09:55
06/17/21
09:55
T

AT&T

$29.05 /

-0.01 (-0.03%)

, BK

BNY Mellon

$51.37 /

+0.125 (+0.24%)

, SWK

Stanley Black & Decker

$197.89 /

+1.13 (+0.57%)

, PDCO

Patterson Companies

$36.76 /

+1.35 (+3.81%)

, BOOT

Boot Barn

$77.59 /

+2.31 (+3.07%)

Catch up on today's…

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AT&T (T) upgraded to Sector Perform from Underperform at Scotiabank with analyst Jeffrey Fan saying the stock over the past two has underperformed at down 9% compared to Verizon's (VZ) down 2% and the up 46% for the S&P 500 Index. 2. BNY Mellon (BK) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Michael Brown expecting the "receive positive news on the capital return front," and longer term the "considerable rate headwinds should flip to meaningful tailwinds" for the trust banks. 3. Stanley Black & Decker (SWK) upgraded to Buy from Hold at Gabelli with analyst Justin Bergner citing his increasing confidence in growth driven by e-commerce, the Black & Decker brand revitalization, and "sustained ex-urban living." 4. Patterson Companies (PDCO) upgraded to Overweight from Neutral at Piper Sandler with analyst Jason Bednar saying he would be a buyer of the stock ahead of next week's fiscal Q4 earnings release. 5. Boot Barn (BOOT) upgraded to Buy from Neutral at Citi with analyst Steven Zaccone viewing Boot Barn as an attractive play on the economic reopening in the near- to medium-term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
T AT&T
$29.05 /

-0.01 (-0.03%)

SWK Stanley Black & Decker
$197.89 /

+1.13 (+0.57%)

PDCO Patterson Companies
$36.76 /

+1.35 (+3.81%)

BOOT Boot Barn
$77.59 /

+2.31 (+3.07%)

BK BNY Mellon
$51.37 /

+0.125 (+0.24%)

T AT&T
$29.05 /

-0.01 (-0.03%)

06/17/21 Scotiabank
AT&T upgraded to Sector Perform on reduced secular risk at Scotiabank
06/16/21 Scotiabank
AT&T upgraded to Sector Perform from Underperform at Scotiabank
06/16/21 Pivotal Research
Dish upgraded to Buy from Hold at Pivotal Research
05/24/21 Morgan Stanley
AT&T price target lowered to $32 from $34 at Morgan Stanley
BK BNY Mellon
$51.37 /

+0.125 (+0.24%)

06/17/21 Keefe Bruyette
BNY Mellon upgraded to Outperform from Market Perform at Keefe Bruyette
04/21/21 Citi
BNY Mellon price target lowered to $56 from $58 at Citi
04/09/21 Deutsche Bank
BNY Mellon price target raised to $54 from $50 at Deutsche Bank
04/07/21 Barclays
BNY Mellon price target raised to $57 from $55 at Barclays
SWK Stanley Black & Decker
$197.89 /

+1.13 (+0.57%)

06/17/21 Gabelli
Stanley Black & Decker upgraded to Buy from Hold at Gabelli
04/13/21 Deutsche Bank
Stanley Black & Decker price target raised to $221 from $215 at Deutsche Bank
04/07/21 JPMorgan
Stanley Black & Decker price target raised to $206 from $200 at JPMorgan
04/06/21 Barclays
Stanley Black & Decker price target raised to $219 from $214 at Barclays
PDCO Patterson Companies
$36.76 /

+1.35 (+3.81%)

06/17/21 Piper Sandler
Patterson Companies upgraded to Overweight from Neutral at Piper Sandler
03/03/21 Piper Sandler
Piper stays Neutral Patterson despite execution due to 'lingering uncertainty'
12/30/20 Piper Sandler
Patterson contract loss unexpected but manageable, says Piper Sandler
12/03/20 Barclays
Patterson Companies price target raised to $25 from $21 at Barclays
BOOT Boot Barn
$77.59 /

+2.31 (+3.07%)

06/17/21 Citi
Boot Barn upgraded to Buy from Neutral at Citi
06/11/21 Baird
Boot Barn price target raised to $92 from $60 at Baird
05/13/21 Craig-Hallum
Boot Barn price target raised to $68 from $54 at Craig-Hallum
05/13/21 Baird
Boot Barn elevated to bullish Fresh Pick at Baird
T AT&T
$29.05 /

-0.01 (-0.03%)

SWK Stanley Black & Decker
$197.89 /

+1.13 (+0.57%)

PDCO Patterson Companies
$36.76 /

+1.35 (+3.81%)

BOOT Boot Barn
$77.59 /

+2.31 (+3.07%)

BK BNY Mellon
$51.37 /

+0.125 (+0.24%)

T AT&T
$29.05 /

-0.01 (-0.03%)

SWK Stanley Black & Decker
$197.89 /

+1.13 (+0.57%)

BK BNY Mellon
$51.37 /

+0.125 (+0.24%)

T AT&T
$29.05 /

-0.01 (-0.03%)

SWK Stanley Black & Decker
$197.89 /

+1.13 (+0.57%)

BOOT Boot Barn
$77.59 /

+2.31 (+3.07%)

BK BNY Mellon
$51.37 /

+0.125 (+0.24%)

T AT&T
$29.05 /

-0.01 (-0.03%)

BOOT Boot Barn
$77.59 /

+2.31 (+3.07%)

Hot Stocks
Lordstown clarifies recent executive remarks, has 'no binding purchase orders' » 08:44
06/17/21
06/17
08:44
06/17/21
08:44
RIDE

Lordstown Motors

$10.77 /

+0.48 (+4.66%)

In a regulatory filing,…

In a regulatory filing, Lordstown Motors stated: "As previously disclosed in our Form 10-K/A for the year ended December 31, 2020, filed with the Securities and Exchange Commission on June 8, 2021, an important aspect of our sales and marketing strategy involves pursuing relationships with specialty upfitting and fleet management companies to incorporate the Endurance into their fleet management programs. Fleet management companies sometimes purchase vehicles and then lease them to their own customers. In other instances, fleet management companies facilitate purchasing or leasing of vehicles by their customers which are generally large fleets... These vehicle purchase agreements generally include a projected buyer order schedule over the 3 to 5 year life of the agreement, and may be terminated by either party at will on 30 days' notice. They do not commit the counterparties to purchase vehicles, but we believe that they provide us with a significant indicator of demand for the Endurance. To clarify recent remarks by company executives at the Automotive Press Association online media event on June 15, although these vehicle purchase agreements provide us with a significant indicator of demand for the Endurance, these agreements do not represent binding purchase orders or other firm purchase commitments. As previously disclosed in our Form 10-K/A for the year ended December 31, 2020, filed with the Securities and Exchange Commission on June 8, 2021, to date, we have engaged in limited marketing activities and we have no binding purchase orders or commitments from customers."

ShowHide Related Items >><<
RIDE Lordstown Motors
$10.77 /

+0.48 (+4.66%)

RIDE Lordstown Motors
$10.77 /

+0.48 (+4.66%)

06/14/21 Morgan Stanley
Lordstown management change 'important first step,' says Morgan Stanley
06/14/21 R.F. Lafferty
R.F. Lafferty downgrades Lordstown to Sell with $3 target on uncertainty
06/14/21 R.F. Lafferty
Lordstown Motors downgraded to Sell from Hold at R.F. Lafferty
06/10/21 Morgan Stanley
Morgan Stanley removes Lordstown rating, says market may be underestimating risk
RIDE Lordstown Motors
$10.77 /

+0.48 (+4.66%)

RIDE Lordstown Motors
$10.77 /

+0.48 (+4.66%)

RIDE Lordstown Motors
$10.77 /

+0.48 (+4.66%)

RIDE Lordstown Motors
$10.77 /

+0.48 (+4.66%)

Recommendations
KeyBanc says Netflix tracking below estimates, sees light at end of the tunnel » 08:03
06/17/21
06/17
08:03
06/17/21
08:03
NFLX

Netflix

$492.54 /

+0.99 (+0.20%)

KeyBanc analyst Justin…

KeyBanc analyst Justin Patterson believes data suggest Netflix is tracking below his/Street Q2 net add estimates of 0.8M/1.0M. The analyst attributes this to a lighter content slate and more time spent outdoors. While he suspects this dynamic could lead to soft net add guidance for Q3, Patterson sees light at the end of the tunnel with the return of Money Heist and Witcher. As net add trends normalize, the analyst believes investors will focus on Netflix's 30%-plus EPS growth, reasonable valuation, and favorable risk/reward. He reiterates an Overweight rating and a price target of $650 on the shares.

ShowHide Related Items >><<
NFLX Netflix
$492.54 /

+0.99 (+0.20%)

NFLX Netflix
$492.54 /

+0.99 (+0.20%)

06/16/21 JPMorgan
JPMorgan 'incrementally positive' on Netflix into second half content slate
06/01/21 KGI Securities
Netflix initiated with a Neutral at KGI Securities
05/27/21 Stifel
Stifel sees 'minimal impact' to Netflix from Amazon's MGM acquisition
05/27/21 Benchmark
Streaming field 'looking ever less unipolar around Netflix,' says Benchmark
NFLX Netflix
$492.54 /

+0.99 (+0.20%)

NFLX Netflix
$492.54 /

+0.99 (+0.20%)

NFLX Netflix
$492.54 /

+0.99 (+0.20%)

NFLX Netflix
$492.54 /

+0.99 (+0.20%)

Hot Stocks
Lordstown Motors appoints of Whitcomb as Vice President » 07:10
06/17/21
06/17
07:10
06/17/21
07:10
RIDE

Lordstown Motors

$10.77 /

+0.48 (+4.66%)

Lordstown Motors has…

Lordstown Motors has announced senior automotive executive John Whitcomb has joined the company as Vice President, Global Commercial Operations, effective June 21, 2021. Whitcomb will be responsible for driving the company's overall go-to-market strategy ahead of the start of production of the Lordstown Endurance in late-September 2021. In the newly created role, Mr. Whitcomb will develop the strategic business model for Lordstown Motors' sales and service footprint, working alongside the team to establish a national sales network. He will be responsible for developing service and after-sales strategies and processes as the company prepares for production. Additionally, he will be tasked with exploring long term international strategies to determine where and when to expand.

ShowHide Related Items >><<
RIDE Lordstown Motors
$10.77 /

+0.48 (+4.66%)

RIDE Lordstown Motors
$10.77 /

+0.48 (+4.66%)

06/14/21 Morgan Stanley
Lordstown management change 'important first step,' says Morgan Stanley
06/14/21 R.F. Lafferty
R.F. Lafferty downgrades Lordstown to Sell with $3 target on uncertainty
06/14/21 R.F. Lafferty
Lordstown Motors downgraded to Sell from Hold at R.F. Lafferty
06/10/21 Morgan Stanley
Morgan Stanley removes Lordstown rating, says market may be underestimating risk
RIDE Lordstown Motors
$10.77 /

+0.48 (+4.66%)

RIDE Lordstown Motors
$10.77 /

+0.48 (+4.66%)

RIDE Lordstown Motors
$10.77 /

+0.48 (+4.66%)

RIDE Lordstown Motors
$10.77 /

+0.48 (+4.66%)

Periodicals
Airbnb, Vrbo loosen new host requirements to increase rental listing, WSJ report » 06:28
06/17/21
06/17
06:28
06/17/21
06:28
ABNB

Airbnb

$149.22 /

-2.56 (-1.69%)

, EXPE

Expedia

$167.99 /

-1.98 (-1.16%)

Vacation-rental brands,…

Vacation-rental brands, such as Airbnb (ABNB) and Expedia's (EXPE) Vrbo, have made it easier to become a host in an effort to meet customer demand for vacation homes near beaches, national parks, and other nonurban areas, Dave Sebastian of The Wall Street Journal reports. Airbnb reduced the sign-up process of new hosts to 10 steps from dozens while Vrbo launched a program that allows Airbnb hosts to transfer their ratings to Vrbo. Reference Link

ShowHide Related Items >><<
EXPE Expedia
$167.99 /

-1.98 (-1.16%)

ABNB Airbnb
$149.22 /

-2.56 (-1.69%)

ABNB Airbnb
$149.22 /

-2.56 (-1.69%)

06/09/21 Loop Capital
Airbnb price target lowered to $195 from $240 at Loop Capital
05/26/21 RBC Capital
Airbnb initiated with an Outperform at RBC Capital
05/24/21 Truist
Airbnb's new flexiblity features 'particularly promising,' says Truist
05/21/21 Morgan Stanley
Airbnb price target lowered to $125 from $160 at Morgan Stanley
EXPE Expedia
$167.99 /

-1.98 (-1.16%)

05/26/21 RBC Capital
Expedia assumed with a Sector Perform at RBC Capital
05/12/21 Citi
Expedia price target raised to $179 from $160 at Citi
05/07/21 BTIG
Expedia price target raised to $210 from $180 at BTIG
05/07/21 Credit Suisse
Expedia price target raised to $198 from $168 at Credit Suisse
EXPE Expedia
$167.99 /

-1.98 (-1.16%)

ABNB Airbnb
$149.22 /

-2.56 (-1.69%)

  • 10
    Dec
EXPE Expedia
$167.99 /

-1.98 (-1.16%)

ABNB Airbnb
$149.22 /

-2.56 (-1.69%)

EXPE Expedia
$167.99 /

-1.98 (-1.16%)

ABNB Airbnb
$149.22 /

-2.56 (-1.69%)

EXPE Expedia
$167.99 /

-1.98 (-1.16%)

ABNB Airbnb
$149.22 /

-2.56 (-1.69%)

Conference/Events
European Hematology Association to hold virtual meeting » 04:55
06/17/21
06/17
04:55
06/17/21
04:55
APTO

Aptose Biosciences

$3.39 /

-0.115 (-3.29%)

, MBIO

Mustang Bio

$3.48 /

-0.09 (-2.52%)

, QURE

uniQure

$34.41 /

-0.015 (-0.04%)

, RIGL

Rigel Pharmaceuticals

$4.20 /

-0.07 (-1.64%)

, MGTA

Magenta Therapeutics

$11.13 /

-0.2 (-1.77%)

, MEIP

MEI Pharma

$3.32 /

+0.22 (+7.10%)

, CRIS

Curis

$7.58 /

-0.07 (-0.92%)

, XLRN

Acceleron

$126.85 /

-1.78 (-1.38%)

, EPZM

Epizyme

$8.81 /

+0.025 (+0.28%)

, INCY

Incyte

$83.13 /

+0.44 (+0.53%)

, ORTX

Orchard Therapeutics

$4.79 /

-0.06 (-1.24%)

, TGTX

TG Therapeutics

$36.64 /

-0.8 (-2.14%)

, EQ

Equillium

$5.87 /

-0.17 (-2.81%)

, JAZZ

Jazz Pharmaceuticals

$181.08 /

-2.19 (-1.19%)

, VRTX

Vertex Pharmaceuticals

$187.51 /

-1.43 (-0.76%)

, SGEN

Seagen

$151.42 /

-1.93 (-1.26%)

, IMRA

Imara

$7.76 /

-0.5 (-6.05%)

, GBT

Global Blood Therapeutics

$38.21 /

-1.39 (-3.51%)

, BGNE

BeiGene

$333.73 /

+2.27 (+0.68%)

, APLS

Apellis

$59.71 /

-0.97 (-1.60%)

, AGIO

Agios Pharmaceuticals

$58.82 /

+0.63 (+1.08%)

, FMTX

Forma Therapeutics

$24.23 /

+0.1 (+0.41%)

, KROS

Keros Therapeutics

$52.91 /

+0.32 (+0.61%)

, CYAD

Celyad

$5.33 /

-0.11 (-2.02%)

, ALXN

Alexion

$180.56 /

-1.34 (-0.74%)

EHA 2021 Virtual Congress…

EHA 2021 Virtual Congress to be held on June 9-17. Webcast Link

ShowHide Related Items >><<
XLRN Acceleron
$126.85 /

-1.78 (-1.38%)

VRTX Vertex Pharmaceuticals
$187.51 /

-1.43 (-0.76%)

TGTX TG Therapeutics
$36.64 /

-0.8 (-2.14%)

SGEN Seagen
$151.42 /

-1.93 (-1.26%)

RIGL Rigel Pharmaceuticals
$4.20 /

-0.07 (-1.64%)

QURE uniQure
$34.41 /

-0.015 (-0.04%)

ORTX Orchard Therapeutics
$4.79 /

-0.06 (-1.24%)

MGTA Magenta Therapeutics
$11.13 /

-0.2 (-1.77%)

MEIP MEI Pharma
$3.32 /

+0.22 (+7.10%)

MBIO Mustang Bio
$3.48 /

-0.09 (-2.52%)

KROS Keros Therapeutics
$52.91 /

+0.32 (+0.61%)

JAZZ Jazz Pharmaceuticals
$181.08 /

-2.19 (-1.19%)

INCY Incyte
$83.13 /

+0.44 (+0.53%)

IMRA Imara
$7.76 /

-0.5 (-6.05%)

GBT Global Blood Therapeutics
$38.21 /

-1.39 (-3.51%)

FMTX Forma Therapeutics
$24.23 /

+0.1 (+0.41%)

EQ Equillium
$5.87 /

-0.17 (-2.81%)

EPZM Epizyme
$8.81 /

+0.025 (+0.28%)

CYAD Celyad
$5.33 /

-0.11 (-2.02%)

CRIS Curis
$7.58 /

-0.07 (-0.92%)

BGNE BeiGene
$333.73 /

+2.27 (+0.68%)

APTO Aptose Biosciences
$3.39 /

-0.115 (-3.29%)

APLS Apellis
$59.71 /

-0.97 (-1.60%)

ALXN Alexion
$180.56 /

-1.34 (-0.74%)

AGIO Agios Pharmaceuticals
$58.82 /

+0.63 (+1.08%)

APTO Aptose Biosciences
$3.39 /

-0.115 (-3.29%)

02/22/21 JonesTrading
Aptose Biosciences resumed with a Buy at JonesTrading
10/19/20 Cantor Fitzgerald
Aptose Biosciences initiated with an Overweight at Cantor Fitzgerald
09/22/20 Alliance Global Partners
Aptose Biosciences initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
MBIO Mustang Bio
$3.48 /

-0.09 (-2.52%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
QURE uniQure
$34.41 /

-0.015 (-0.04%)

06/16/21 Chardan
uniQure on track for 'powerful' Huntington's catalyst, says Chardan
06/14/21 BTIG
uniQure initiated with a Buy at BTIG
05/20/21 UBS
uniQure initiated with a Neutral at UBS
05/19/21 H.C. Wainwright
uniQure price target raised to $90 from $80 at H.C. Wainwright
RIGL Rigel Pharmaceuticals
$4.20 /

-0.07 (-1.64%)

06/11/21 BMO Capital
Rigel Pharmaceuticals coverage transferred at BMO Capital
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
04/13/21 Piper Sandler
Rigel results in severe COVID-19 trial 'pretty dramatic,' says Piper Sandler
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
MGTA Magenta Therapeutics
$11.13 /

-0.2 (-1.77%)

06/14/21 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
05/18/21 B. Riley
Magenta Therapeutics initiated with a Buy, $21 target at B. Riley
05/17/21 B. Riley
Magenta Therapeutics initiated with a Buy at B. Riley
05/13/21 Mizuho
Magenta Therapeutics price target raised to $17 from $16 at Mizuho
MEIP MEI Pharma
$3.32 /

+0.22 (+7.10%)

04/26/21 Wells Fargo
MEI Pharma likely to expand scope of voruciclib development, says Wells Fargo
10/12/20 Brookline
MEI Pharma initiated with a Buy at Brookline
09/22/20 Alliance Global Partners
MEI Pharma initiated with a Buy at Alliance Global Partners
07/06/20 Truist
MEI Pharma price target lowered to $12 from $16 at SunTrust
CRIS Curis
$7.58 /

-0.07 (-0.92%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
XLRN Acceleron
$126.85 /

-1.78 (-1.38%)

06/11/21 H.C. Wainwright
Acceleron results for Phase 2 BEYOND study 'impressive,' says H.C. Wainwright
05/19/21 Piper Sandler
Piper remains bullish on Acceleron after Phase 2 PULSAR OLE, SPECTRA updates
04/26/21 Credit Suisse
Acceleron assumed with an Outperform at Credit Suisse
03/23/21
Fly Intel: Top five analyst downgrades
EPZM Epizyme
$8.81 /

+0.025 (+0.28%)

05/07/21 SVB Leerink
Epizyme upgraded to Outperform from Market Perform at SVB Leerink
04/23/21 Cowen
Epizyme transferred with Outperform at Cowen
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
INCY Incyte
$83.13 /

+0.44 (+0.53%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
ORTX Orchard Therapeutics
$4.79 /

-0.06 (-1.24%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
TGTX TG Therapeutics
$36.64 /

-0.8 (-2.14%)

04/20/21
Fly Intel: Top five analyst initiations
04/20/21 Goldman Sachs
TG Therapeutics initiated with a Neutral at Goldman Sachs
04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
EQ Equillium
$5.87 /

-0.17 (-2.81%)

03/03/21
Fly Intel: Top five analyst initiations
03/03/21 JonesTrading
Equillium initiated with a Buy at JonesTrading
11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
JAZZ Jazz Pharmaceuticals
$181.08 /

-2.19 (-1.19%)

05/19/21
Fly Intel: Top five analyst initiations
05/19/21 JPMorgan
Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
05/17/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
VRTX Vertex Pharmaceuticals
$187.51 /

-1.43 (-0.76%)

06/14/21 Truist
Vertex Pharmaceuticals price target raised to $331 from $305 at Truist
06/14/21 SVB Leerink
Vertex Pharmaceuticals price target lowered to $200 from $250 at SVB Leerink
06/14/21 Deutsche Bank
Grifols upgraded to Buy from Hold at Deutsche Bank
06/13/21 Piper Sandler
Vertex Pharmaceuticals price target lowered to $261 from $347 at Piper Sandler
SGEN Seagen
$151.42 /

-1.93 (-1.26%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
IMRA Imara
$7.76 /

-0.5 (-6.05%)

03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
GBT Global Blood Therapeutics
$38.21 /

-1.39 (-3.51%)

05/07/21 Cantor Fitzgerald
Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald
05/06/21 Piper Sandler
Global Blood price target lowered to $45 from $50 at Piper Sandler
04/14/21
Fly Intel: Top five analyst initiations
04/14/21 SVB Leerink
SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform
BGNE BeiGene
$333.73 /

+2.27 (+0.68%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
APLS Apellis
$59.71 /

-0.97 (-1.60%)

05/20/21 UBS
Apellis initiated with a Buy at UBS
05/18/21 BMO Capital
Apellis price target raised to $68 from $64 at BMO Capital
05/17/21 Oppenheimer
Apellis price target raised to $67 from $64 at Oppenheimer
05/17/21 Raymond James
Apellis price target raised to $115 from $104 at Raymond James
AGIO Agios Pharmaceuticals
$58.82 /

+0.63 (+1.08%)

06/10/21 H.C. Wainwright
Agios Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/30/21 Goldman Sachs
Agios Pharmaceuticals reinstated with a Neutral at Goldman Sachs
04/30/21 Barclays
Agios Pharmaceuticals price target raised to $70 from $65 at Barclays
03/30/21 Piper Sandler
Agios should rally on Forma Therapeutics data, says Piper Sandler
FMTX Forma Therapeutics
$24.23 /

+0.1 (+0.41%)

03/31/21 H.C. Wainwright
Forma Therapeutics price target raised to $55 from $53 at H.C. Wainwright
02/17/21
Fly Intel: Top five analyst initiations
02/17/21 Oppenheimer
Forma Therapeutics initiated with an Outperform at Oppenheimer
KROS Keros Therapeutics
$52.91 /

+0.32 (+0.61%)

12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
12/08/20 Piper Sandler
Keros Therapeutics price target raised to $95 from $75 at Piper Sandler
11/18/20 Piper Sandler
Keros Therapeutics price target raised to $75 from $55 at Piper Sandler
CYAD Celyad
$5.33 /

-0.11 (-2.02%)

03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
12/08/20 H.C. Wainwright
Celyad price target lowered to $18 from $22 at H.C. Wainwright
ALXN Alexion
$180.56 /

-1.34 (-0.74%)

05/05/21
Fly Intel: Top five analyst upgrades
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
05/03/21 SVB Leerink
Alexion price target raised to $173 from $156 at SVB Leerink
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
XLRN Acceleron
$126.85 /

-1.78 (-1.38%)

VRTX Vertex Pharmaceuticals
$187.51 /

-1.43 (-0.76%)

TGTX TG Therapeutics
$36.64 /

-0.8 (-2.14%)

SGEN Seagen
$151.42 /

-1.93 (-1.26%)

RIGL Rigel Pharmaceuticals
$4.20 /

-0.07 (-1.64%)

QURE uniQure
$34.41 /

-0.015 (-0.04%)

ORTX Orchard Therapeutics
$4.79 /

-0.06 (-1.24%)

MGTA Magenta Therapeutics
$11.13 /

-0.2 (-1.77%)

MEIP MEI Pharma
$3.32 /

+0.22 (+7.10%)

MBIO Mustang Bio
$3.48 /

-0.09 (-2.52%)

KROS Keros Therapeutics
$52.91 /

+0.32 (+0.61%)

JAZZ Jazz Pharmaceuticals
$181.08 /

-2.19 (-1.19%)

INCY Incyte
$83.13 /

+0.44 (+0.53%)

IMRA Imara
$7.76 /

-0.5 (-6.05%)

GBT Global Blood Therapeutics
$38.21 /

-1.39 (-3.51%)

FMTX Forma Therapeutics
$24.23 /

+0.1 (+0.41%)

EQ Equillium
$5.87 /

-0.17 (-2.81%)

EPZM Epizyme
$8.81 /

+0.025 (+0.28%)

CRIS Curis
$7.58 /

-0.07 (-0.92%)

BGNE BeiGene
$333.73 /

+2.27 (+0.68%)

APTO Aptose Biosciences
$3.39 /

-0.115 (-3.29%)

APLS Apellis
$59.71 /

-0.97 (-1.60%)

ALXN Alexion
$180.56 /

-1.34 (-0.74%)

AGIO Agios Pharmaceuticals
$58.82 /

+0.63 (+1.08%)

  • 15
    Dec
  • 09
    Dec
  • 11
    Dec
  • 02
    Dec
  • 13
    Nov
  • 14
    Aug
  • 16
    Jul
  • 01
    Jul
  • 25
    Jun
  • 19
    Jun
VRTX Vertex Pharmaceuticals
$187.51 /

-1.43 (-0.76%)

RIGL Rigel Pharmaceuticals
$4.20 /

-0.07 (-1.64%)

ORTX Orchard Therapeutics
$4.79 /

-0.06 (-1.24%)

JAZZ Jazz Pharmaceuticals
$181.08 /

-2.19 (-1.19%)

INCY Incyte
$83.13 /

+0.44 (+0.53%)

EPZM Epizyme
$8.81 /

+0.025 (+0.28%)

VRTX Vertex Pharmaceuticals
$187.51 /

-1.43 (-0.76%)

TGTX TG Therapeutics
$36.64 /

-0.8 (-2.14%)

SGEN Seagen
$151.42 /

-1.93 (-1.26%)

QURE uniQure
$34.41 /

-0.015 (-0.04%)

MBIO Mustang Bio
$3.48 /

-0.09 (-2.52%)

JAZZ Jazz Pharmaceuticals
$181.08 /

-2.19 (-1.19%)

INCY Incyte
$83.13 /

+0.44 (+0.53%)

IMRA Imara
$7.76 /

-0.5 (-6.05%)

GBT Global Blood Therapeutics
$38.21 /

-1.39 (-3.51%)

EQ Equillium
$5.87 /

-0.17 (-2.81%)

CRIS Curis
$7.58 /

-0.07 (-0.92%)

APTO Aptose Biosciences
$3.39 /

-0.115 (-3.29%)

APLS Apellis
$59.71 /

-0.97 (-1.60%)

ALXN Alexion
$180.56 /

-1.34 (-0.74%)

VRTX Vertex Pharmaceuticals
$187.51 /

-1.43 (-0.76%)

INCY Incyte
$83.13 /

+0.44 (+0.53%)

FMTX Forma Therapeutics
$24.23 /

+0.1 (+0.41%)

EQ Equillium
$5.87 /

-0.17 (-2.81%)

CRIS Curis
$7.58 /

-0.07 (-0.92%)

APLS Apellis
$59.71 /

-0.97 (-1.60%)

ALXN Alexion
$180.56 /

-1.34 (-0.74%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.